11.07.2019 23:00:24
|
Illumina Lowers Revenue Outlook, Shares Sink 16%
(RTTNews) - Shares of Illumina Inc. (ILMN) plunged nearly 16% in the extended session Thursday after the genetics company reported a weak preliminary revenues for the second quarter and lowered its full-year 2019 revenue guidance.
For the second quarter, the company expects revenues of about $835 million, up from $830 million a year ago. Analysts polled by Thomson Reuters currently estimate revenues of $888.18 million for the quarter.
The company said its second-quarter results were impacted by about $50 million lower revenues due to population genomics initiatives, ongoing weakness in the direct-to-consumer market and lower sales associated with its non-high-throughput sequencing systems and consumables.
"We are obviously disappointed with our second quarter financial results. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, President and CEO.
"Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics."
Moving ahead, Illumina said it now expects fiscal year revenue growth of about 6%. Previously, while reporting first quarter results, the company said it expects revenue growth of 13% to 14% in 2019. Analysts currently estimate revenue growth of 13.10%.
ILMN closed Thursday's trading at $363.66, down $9.04 or 2.43%, on the Nasdaq. The stock further dropped $57.91 or 15.92% in the after-hours trade.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Illumina Inc.mehr Nachrichten
20.12.24 |
S&P 500-Wert Illumina-Aktie: So viel Verlust hätte ein Illumina-Investment von vor 10 Jahren eingebracht (finanzen.at) | |
18.12.24 |
Schwacher Handel in New York: NASDAQ 100 am Mittwochmittag im Minus (finanzen.at) | |
13.12.24 |
Gewinne in New York: NASDAQ 100 mittags auf grünem Terrain (finanzen.at) | |
13.12.24 |
S&P 500-Titel Illumina-Aktie: So viel Verlust hätte ein Illumina-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
11.12.24 |
Starker Wochentag in New York: NASDAQ 100-Anleger greifen mittags zu (finanzen.at) | |
11.12.24 |
Börse New York: NASDAQ 100 bewegt sich zum Handelsstart im Plus (finanzen.at) | |
10.12.24 |
Pluszeichen in New York: NASDAQ 100 zum Handelsstart in Grün (finanzen.at) | |
06.12.24 |
S&P 500-Wert Illumina-Aktie: So viel hätten Anleger mit einem Investment in Illumina von vor 3 Jahren verloren (finanzen.at) |